Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Biotech-focused investment firm Frazier Life Sciences launched Callio Therapeutics, a cancer treatment startup with ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

A former employee of Stanford University was found guilty of accessing a clinical research database for a multisite breast ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) ...

Roche announces positive results from phase III OUtMATCH study of Xolair for the treatment of one or more food allergies: Basel Tuesday, March 4, 2025, 12:00 Hrs [IST] Roche annou ...

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...